Darifenacin Impurities

veeprho banner
Parent Drug Name Name of Impurity Catalogue No.
Darifenacin Darifenacin Bromo impurity VL1530004View CAS 127264-14-6
Darifenacin Darifenacin Cyano Pyrrolidine Impurity VL1530005View CAS 133099-11-3
Darifenacin Darifenacin Impurity 3 VL1530006View CAS 86-29-3
Darifenacin Darifenacin Impurity A VL1530001View CAS 1048979-16-3
Darifenacin Darifenacin N-Oxide VL1530009View CAS 1391080-40-2
Darifenacin R-Isomer of Darifenacin Hydrobromide VL1530002View CAS 1092800-15-1
Darifenacin 1-Tosyl-3-pyrrolidinol Tosylate (Darifenacin Impurity) VL1530007View CAS 131912-34-0
Darifenacin 2, 3-dihydro-1-benzofuran-5-yl-acetic acid (Darifenacin Impurity) VL1530008View CAS 69999-16-2

Request a quote

1048979-16-3: Darifenacin Impurity A

1048979-16-3: Darifenacin Impurity A
Catalogue No.

VL1530001
CAS No.

1048979-16-3
Molecular Formula

C28H29NO3
Molecular Weight

427.55
Parent drug

Darifenacin
IUPAC Name

2-((S)-1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetic acid
Synonyms

Darifenacin Carboxylic Acid
References

Nilvebrant, L., et al. “Tolterodine-a New Bladder Selective Muscarinic Receptor Antagonist: Preclinical Pharmacological and Clinical Data.” Life Sciences, vol. 60, no. 13-14, Feb. 1997, pp. 1129–36, https://doi.org/10.1016/s0024-3205(97)00057-x.Croom, Katherine F., and Gillian M. Keating. “Darifenacin.” Drugs & Aging, vol. 21, no. 13, 2004, pp. 885–92, https://doi.org/10.2165/00002512-200421130-00005.
Status

In-stock
ListName

Darifenacin Impurity A
Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url